Kamada (KMDA) EBITDA (2012 - 2026)
Kamada's (KMDA) quarterly EBITDA came in at $9.5 million in Q2 2026, up 34.49% on a YoY basis from $7.1 million in Q2 2025, and up 36.78% quarter-over-quarter from $7.0 million in Q1 2026.
Analysis
Kamada (KMDA) EBITDA (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported EBITDA for 15 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA rose 34.49% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $32.1 million (up 10.98% YoY), and the FY2025 full-year result was $42.0 million, up 23.04% from the prior year.
- EBITDA climbed to $9.5 million in Q2 2026 per KMDA's latest filing, from $7.0 million in the prior quarter.
- Across five years, EBITDA topped out at $9.5 million in Q2 2026 and bottomed at -$2.3 million in Q2 2022.
- Historically, EBITDA has averaged $5.3 million across 5 years, with a median of $6.0 million in 2023.
- The sharpest annual moves came in 2022 and 2024: EBITDA tumbled 319.31% in 2022, then jumped 1297.58% in 2024.
- Over 5 years, EBITDA stood at $7.2 million in 2022, then fell by 12.29% to $6.4 million in 2023, then soared by 37.72% to $8.8 million in 2024, then declined by 10.78% to $7.8 million in 2025, then rose by 21.75% to $9.5 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $9.5 million, $7.0 million, and $7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | 9.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.51 Mn |
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | 7.81 Mn |
| Sep 30, 2025 | 7.82 Mn |
| Jun 30, 2025 | 7.07 Mn |
| Mar 31, 2025 | 7.80 Mn |
| Dec 31, 2024 | 8.76 Mn |
| Sep 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | 5.64 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 6.36 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 289,000.00 |
| Dec 31, 2022 | 7.25 Mn |
| Sep 30, 2022 | 2.56 Mn |
| Jun 30, 2022 | -2.29 Mn |
| Mar 31, 2022 | 3.29 Mn |
| Dec 31, 2021 | -1.28 Mn |
| Sep 30, 2021 | -804,000.00 |